

Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)

Bernd J. Schmitz-Dräger^{a,b} Ekkehardt Bismarck^a Thomas Ebert^a
Roland Starlinger^c Kerstin Dienes^d Bertram Ottillinger^e Peter J. Goebell^b
Stephan Mühlich^f Natalya Benderska-Söder^a Jutta Bergler-Klein^g
Oliver W. Hakenberg^h

^aUrologie 24, St. Theresien-Krankenhaus, Nuremberg, Germany; ^bDepartment of Urology and Pediatric Urology, Friedrich-Alexander University, Erlangen, Germany; ^cSandoz GmbH, Kundl, Austria; ^dHexal AG, Holzkirchen, Germany; ^eOttillinger Life Sciences, Brunnthal, Germany; ^fUrology Practice, Bamberg, Germany; ^gDepartment of Cardiology, University Clinic of Internal Medicine II, Medical University of Vienna, Vienna, Austria; ^hDepartment of Urology, University of Rostock, Rostock, Germany

Keywords

Prostate cancer · Hormone-sensitive prostate cancer · Noninterventional study · Androgen deprivation therapy · Leuporelin · Cardio-oncology · Cardiovascular risk · Cardiotoxicity

Abstract

Introduction: LEAN is a prospective, multicenter, non-interventional, German cohort study in patients with locally advanced and metastatic hormone-sensitive prostate cancer (PC). This analysis explores the efficacy and safety of leuporelin in patients with PC and an indication for androgen deprivation therapy (ADT) in routine practice. **Methods:** Safety assessment focused on the incidence of major adverse cardiovascular (CV) events (MACEs; a composite of all-cause death, myo-

cardial infarction, or stroke) over the 12-month study period. Patients initiating ADT before enrollment were excluded from the analysis. **Results:** Of the 1,372 patients included, MACEs occurred in 57 (4.2%) patients and in 18/532 (3.4%) versus 39/840 (4.6%) patients without and with a pre-existing CV comorbidity, respectively ($p = 0.264$). Of the 57 MACEs, 17 were CV events and 20 were considered PC-related events; in 20 patients, events were classed as “other” or the context remained unknown. Only one MACE, nonserious arrhythmia, was considered drug related by the urologist. Of the 52 deaths reported in patients with MACEs, 12 were related to a CV event and 20 were related to disease progression. **Conclusion:** In a large European patient cohort, leuporelin-based ADT demonstrated an acceptable safety profile, with a low incidence of CV events.

© 2025 The Author(s).
Published by S. Karger AG, Basel

Introduction

The addition of chemotherapy and novel hormonal therapy to treatment of locally advanced and metastatic hormone-sensitive prostate cancer (PC) has greatly improved patient prognosis [1–4]. Nevertheless, long-term androgen deprivation therapy (ADT) remains the backbone of current therapeutic concepts [2–4]. The increase in therapeutic intensity, along with improved life expectancy, now requires greater efforts to control treatment side effects.

ADT has been associated with increased cardiovascular (CV) risk in patients with PC [5, 6], and in 2010, the US Food and Drug Administration (FDA) mandated addition of a statement about potentially increased CV risks to product safety information for gonadotrophin-releasing hormone (GnRH) agonists [7]. However, it is unclear whether the mode of testosterone suppression (GnRH agonist or antagonist, or orchiectomy) differentially affects CV risk, especially among patients with pre-existing atherosclerotic CV disease [8–10]. Finally, whether CV events are more frequent in the early phases of treatment or equally distributed over the course of treatment remains unclear [11, 12]. In the current European Society of Cardiology (ESC) cardio-oncology guidelines, baseline and annual CV risk assessment during ADT is recommended [13]. However, it was pointed out that further research is needed to clarify whether GnRH agonists or antagonists are favorable in patients with PC and CV disease.

The LEAN study (<https://drks.de/search/en/trial/DRKS00005643>, “Observation of Leuprone® HEXAL® in treatment practice. Noninterventional study on therapy over time, tolerability profile and on anamnestic factors”), comprising parts I and II, was conducted to expand knowledge on the effectiveness and safety of leuporelin (GnRH agonist) therapy in a real-world setting. This pooled analysis of LEAN focuses on major adverse CV events (MACEs) during the study.

Patients and Methods

Study Description

The LEAN study was a 12-month, multicenter, prospective, noninterventional study conducted between October 2013 and June 2020, involving 190 centers in Germany. In total, 1,802 patients with PC and an indication for ADT were included. Participants were treated with leuporelin 3.6 mg monthly or leuporelin 5 mg every 3 months. Baseline demographic data for each patient were reported by their urologist. Patients also responded to a survey on baseline med-

ications. Patient efficacy and safety data were acquired at baseline and after 3, 6, 9, and 12 months. Interim results from this study (LEAN I) involving 959 patients were published previously [14]. Due to an update of treatment guidelines in 2016 recommending the addition of systemic docetaxel to ADT in metastatic hormone-sensitive PC [1], the LEAN I protocol was amended and continued as LEAN II, which permitted inclusion of patients receiving ADT in combination with chemotherapy.

Inclusion/Exclusion Criteria

Inclusion/exclusion criteria have been published previously [14]. Patients with PC, an indication for ADT, and life expectancy of >12 months were eligible; there was no upper age limit. Exclusion criteria included surgical castration, hypersensitivity to leuporelin, and therapy with other GnRH agonists/antagonists or polylactic acid. Previous leuporelin treatment for ≤6 months (i.e., short-course ADT) before recruitment was permitted as the goal of LEAN was to assess the effect of ADT over ≥12 months. Nevertheless, for analysis of CV side effects, patients who received ADT prior to recruitment were not considered.

Study Assessment

The safety profile of leuporelin was assessed through documentation of adverse events (AEs) and serious AEs according to the Common Terminology Criteria for Adverse Events [15]. This assessment focused on CV toxicity. For comparability, the definition of MACE was adopted from the PRONOUNCE trial, in which MACE was defined as a composite of all-cause death, myocardial infarction, or stroke over 12 months [8].

Statistical Analysis

Changes in parameters over time were evaluated using appropriate tests (e.g., the paired-samples *t* test for continuous data and Fisher’s exact test for categorical data). All statistical tests performed were descriptive and had no confirmatory character.

Analysis was based on (Fig. 1):

- the full analysis set (FAS), which included all patients who provided written informed consent;
- the safety analysis set (SAS), which included all patients in the FAS who received at least one implant of leuporelin; and
- the modified SAS (mSAS), which included all patients in the SAS who did not violate any of the inclusion/exclusion criteria and presented with plausible data confirming the administration of leuporelin at the initial visit and at least one subsequent visit.




Fig. 1. Trial profile showing allocation of patients to each analysis set. GCP, Good Clinical Practice; FAS, full analysis set; LHRH, luteinizing hormone-releasing hormone; mSAS, modified SAS; SAS, safety analysis set.

Patients receiving ADT before enrollment were excluded from the mSAS as the inclusion of patients tolerating ADT without experiencing a MACE may have led to positive selection bias. Analysis of MACE was therefore restricted to the mSAS.

Results

Patient Population

Of 1,802 patients included in the SAS, 430 (23.9%) patients received leuporelin ≤ 6 months before the study start date and were excluded from this analysis, leaving 1,372 patients in the mSAS (Fig. 1). Baseline demographic data for the mSAS are summarized in Table 1. In the mSAS, 88.0% of patients were aged ≥ 65 years. Pre-existing CV diseases were reported by the urologist in charge in 61.2% of patients and represent the most common comorbidity. At baseline, 53.1% of patients were being concomitantly treated with anti-androgen therapy during the study to prevent flare-ups, but only 2 patients (0.1%) continued receiving anti-androgen therapy. After the protocol change, 32/864 (3.7%) patients (LEAN II) received docetaxel-based chemotherapy at baseline or during follow-up. Approximately 95% of patients in the FAS received 3-monthly leuporelin. Information on baseline

medications obtained from a patient questionnaire (online suppl. Table 1; for all online suppl. material, see <https://doi.org/10.1159/000543985>) suggests that the number of patients suffering from pre-existing CV comorbidity might exceed the figure provided by the physicians. Baseline CV medications were continued as indicated.

Major Adverse CV Events

MACEs (all-cause death, myocardial infarction, or stroke) occurred in 57/1,372 (4.2%) patients in the mSAS and in 18/532 (3.4%) versus 39/840 (4.6%) patients without and with a pre-existing CV comorbidity, respectively. This nonsignificant difference ($p = 0.264$) was present over the whole analysis period (Fig. 2). Of 57 MACEs, 14 events occurred within the first 100 days of observation. Of the 57 MACEs, 20 were classified by the urologist in charge as PC-related events, 17 as CV events (CV death, $n = 12$; acute myocardial infarction, $n = 2$; cerebrovascular accident, $n = 2$; angina pectoris, $n = 1$), and 20 as “other” (general physical health deterioration, $n = 5$; edema, $n = 2$; pneumonia, $n = 2$; other causes, $n = 4$) and of unknown origin (death of unknown cause, $n = 7$). Figure 3 illustrates the time points of MACE occurrences in patients who experienced MACEs. There was no significant difference in the incidence of MACE within age-groups between patients with and without pre-existing CV

Table 1. Baseline demographics and disease characteristics – mSAS

Characteristic	Evaluable patients, <i>n</i>	Result
Age, median (Q1;Q3), years	1,372	76 (71;80)
Mean (SD)		74.6 (7.5)
BMI, mean (SD)	1,365	27.5 (4.1)
≤30 kg/m ² , <i>n</i> (%)		1,063 (77.9)
>30 kg/m ² , <i>n</i> (%)		302 (22.1)
Duration of disease since diagnosis, mean (SD), months	1,294	26.0 (48.9)
ECOG performance status (baseline/visit 1), <i>n</i> (%)	1,371	
Grade 0		835 (60.9)
Grade 1		463 (33.8)
Grade 2		73 (5.3)
Gleason score, %	341	
Grade 6/7a		32.8
Grade 7b		27.0
Grade 8–10		40.2
Pre-existing CV comorbidity, <i>n</i> (%)	1,372	840 (61.2)
Previous radical prostatectomy, <i>n</i> (%)	1,372	378 (27.6)
Radiation therapy, <i>n</i> (%)	1,372	267 (19.5)
Baseline PSA, ng/mL	1,298	
Mean (SD)		28.9 (54.1)
Median (min–max)		8.7 (0.0–350.0)
Baseline testosterone, ng/mL	801	
Mean (SD)		3.96 (2.17)

BMI, body mass index; CV, cardiovascular; ECOG, Eastern Cooperative Oncology Group; mSAS, modified safety analysis set; PSA, prostate-specific antigen; Q1/3, first/third quartile; SD, standard deviation.

comorbidities (<65 years, *n* = 164; 65–79 years, *n* = 863; or ≥80 years, *n* = 345; *p* = 0.6634). The incidence of MACEs within age-groups is shown in Figure 4.

Other Safety Outcomes

Safety outcomes for the mSAS are summarized in Table 2. Overall, 539 (39.3%) patients experienced 1,090 AEs during the study, with hot flushes being the most common AE. In total, 242 (17.6%) patients experienced 434 serious AEs. Of these, 16 (1.2%) patients experienced serious adverse drug reactions, including hot flushes in 5 patients and drug-induced liver injury and pulmonary embolism in 1 patient each. Cardiac disorders were not considered drug related by the investigators, except for 1 case of nonserious arrhythmia.

Of the 52 deaths reported from the 57 patients with MACEs, 12 were related to a CV event and 20 were related to disease progression. Furthermore, within the mSAS, 74 patients withdrew from the study prematurely, 68 (5.0%) at the patient's request, and 6 (0.4%) due to AEs.

Discussion

This study focused on CV outcomes during treatment with leuprorelin. Furthermore, the effect of the addition of chemotherapy to the study protocol and the effect of leuprorelin dosage (1-monthly vs. 3-monthly) were not assessed, given that the proportions of patients who received chemotherapy or who received 1-monthly leuprorelin were very low.

GnRH agonists and antagonists have different mechanisms of action, which can lead to differences in the rate of testosterone decline and follicle-stimulating hormone (FSH) levels. Sustained low FSH levels, as seen with GnRH antagonists, have been reported to be associated with lower rates of MACEs [16]. The literature comparing CV events with GnRH agonists versus antagonists presents conflicting results: the Phase III HERO study compared efficacy and safety outcomes for leuprorelin versus relugolix (GnRH antagonist) in patients with advanced PC. MACEs




Fig. 2. Failure probability plot for developing a MACE with number of patients at risk – mSAS. **a** Overall. **b** Stratified by CV/vascular history. Log-rank $p = 0.2640$. CV, cardiovascular; MACE, major adverse cardiovascular event; mSAS, modified safety analysis set.

(defined as nonfatal myocardial infarction, nonfatal stroke, and all-cause deaths) occurred among 6.2% versus 2.9% of patients treated with leuprorelin and relugolix, respectively, within 12 months of treatment (hazard ratio 0.46; 95% confidence interval [CI], 0.24–0.88). No differences in grade 3/4 (i.e., severe or

life threatening) MACEs were observed between leuprorelin and relugolix (1.3% for both) [12]. Patients with MACEs within 6 months prior to the study were excluded from HERO, and various medications that could affect CV outcomes were prohibited, which may have made the patient population less representative of




Fig. 3. Swimmer plot showing the duration of observation for each patient who experienced a MACE and associated events – mSAS. CV, cardiovascular; MACE, major adverse cardiovascular event; mSAS, modified safety analysis set; PC, prostate cancer.

real-world practice. Moreover, HERO was not powered to assess CV outcomes [17].

The PRONOUNCE trial was a prospective, multi-center, open-label, randomized trial comparing the CV safety of degarelix (GnRH antagonist) versus leuporelin in patients with advanced PC and pre-existing CV disease [8]. The primary outcome was the time to first adjudicated MACE (a composite of death, myocardial infarction, or stroke) through 12 months. The study was terminated prematurely because of the smaller than planned number of participants and events, and no significant difference in MACEs between patients assigned to degarelix (5.5%) and to leuporelin (4.1%) was observed over 12 months ($p = 0.53$) [8].

Several real-world studies report a similar or even lower CV incidence with GnRH agonists versus antagonists. An observational trial reported findings similar to the PRONOUNCE trial, with 3.9% of patients treated with degarelix versus 2.9% treated with leuporelin experiencing a MACE, as defined in PRONOUNCE [18]. Additionally, a study of US electronic medical records for 45,059 men with PC evaluated MACE risk after ADT initiation with GnRH agonists or antagonists. The adjusted risk of MACE was higher with GnRH antagonists versus agonists (hazard ratio 1.62; 95% CI, 1.21–2.18; $p < 0.001$) [19]. Other databases from EudraVigilance and the FDA showed similar incidences of CV events with degarelix (6%) and leuporelin (5%), with a pooled relative risk of total CV events with




Fig. 4. Incidence of MACEs by age-group and CV history – mSAS. CV, cardiovascular; MACE, major adverse cardiovascular event; mSAS, modified safety analysis set.

Table 2. Safety profile of leuprorelin – mSAS focusing on MACEs

Event, n (%)	N = 1,372
AE	539 (39.3)
Adverse drug reaction	240 (17.5)
Serious AE	242 (17.6)
MACE	57 (4.2)
Death	52 (3.8)
CV death	12 (0.9)
Death due to disease progression	20 (1.5)
Unknown or other reason	20 (1.5)
SADR	16 (1.2)

AE, adverse event; CV, cardiovascular; MACE, major adverse cardiovascular event; mSAS, modified safety analysis set; SADR, serious adverse drug reaction.

degarelix versus leuprorelin of 1.28 (95% CI, 0.95–1.44; $p = 0.10$) [20].

Another prospective cohort study in the Asian population compared GnRH agonists versus antagonists using two endpoints, MACE_{PRONOUNCE} (same definition as PRONOUNCE) and MACE_{CVM} (a composite of CV mortality, stroke, and myocardial infarction). GnRH agonist-treated patients had a lower risk of MACE_{PRONOUNCE} ($p < 0.001$) and MACE_{CVM} ($p = 0.027$) over the median follow-up period of 3 years, but not within 1 year of follow-up, compared to GnRH antagonist-treated patients. Among patients without CV risk factors at baseline, GnRH agonist-treated patients had a lower risk of MACE_{PRONOUNCE} ($p < 0.001$) and MACE_{CVM} ($p = 0.001$) than GnRH antagonist-treated

patients, whereas no differences were observed in patients with such risk factors [21].

Two reviews have also explored the influence of GnRH agonists and antagonists on CV events. A Cochrane review of randomized controlled trials comparing degarelix and standard hormonal therapy in men with newly diagnosed advanced PC included 11 studies [9]. A narrative review of epidemiologic studies of GnRH agonists and antagonists and CV outcomes included 71 papers [10]. Neither review identified a conclusive pattern of CV risk with GnRH agonists versus antagonists [9, 10].

Finally, a recent meta-analysis of prospective, randomized trials comparing GnRH antagonists and agonists in patients with PC found that there was insufficient high-quality, randomized evidence to definitively assess the superiority of either GnRH antagonists or GnRH agonists in terms of CV safety, particularly among those with CV comorbidities. Furthermore, the assessments for CV events were not consistent across the 11 identified studies, indicating a need for consistency in defining MACEs [22].

The recent ESC guidelines suggest that a GnRH antagonist rather than an agonist should be considered in patients with pre-existing symptomatic coronary artery disease who require ADT [13]. Current real-world data in patients with PC, including the LEAN study, suggest that there is no difference in CV MACE in patients with or without preexisting stable CV disease at baseline with the agonist leuprorelin. Consistent with the above literature, MACE occurrence in the LEAN pooled study was also quite low despite the higher age and greater comorbidity of patients in this study compared with the interventional studies cited above. Therefore, our data support earlier studies showing that GnRH agonist treatment is well tolerated and has a good safety profile in real-world settings and with concomitant baseline cardiac medications as indicated in patients with CV comorbidities (Table 1; online suppl. Table 1). This is further supported by the low rate of serious adverse drug reactions observed in LEAN.

We note that the number of patients receiving baseline CV medications might exceed the number of patients with CV comorbidities noted at baseline. However, this comparison is flawed as the baseline medication questionnaire was completed by a modified FAS, whereas this analysis of MACE data was in the mSAS. Regardless, the baseline medication data indicate the need for consistent review of CV history of elderly patients with PC.

We further conclude that the use of any definition of MACE that includes all-cause mortality has limitations as outcomes are affected by the underlying patient cohort. While in our “mixed” cohort, 20 of 57 (35%) patients with

MACE were reported to have died from PC, the proportion of patients with MACE would vary in a more selective cohort of patients with metastatic hormone-sensitive PC. In addition, the fact that ADT monotherapy has been superseded by updated guideline recommendations for combination therapy will complicate future assessments of AEs mediated by GnRH agonists and antagonists as androgen receptor inhibitors are also associated with AEs that can overlap with those associated with ADT, including MACEs [1, 23]. Thus, we strongly advocate the use of MACE_{CVM} as proposed by Chan et al. [21] in future studies addressing the question of ADT-related CV complications.

Conclusion

The results from this analysis represent a large European patient population with PC treated with the GnRH agonist leuporelin in real-world clinical practice. While CV monitoring should be a standard part of care for such patients, the results demonstrate that GnRH agonist-based ADT has an acceptable safety profile, with low incidence of CV events. Previous efficacy findings from randomized clinical studies were confirmed without any new safety concerns.

Acknowledgments

Project implementation, quality review, data management, continuous pharmacovigilance operations, and statistical analysis were performed by Institut Dr. Schauerte, Germany, funded by Hexal AG/Sandoz. The authors thank Dan Hami of Titan, OPEN Health Communications, for medical writing support and editorial assistance, funded by Sandoz in accordance with Good Publication Practice (GPP 2022) guidelines (www.ismpp.org/gpp-2022).

Statement of Ethics

All patients have provided written, informed consent to participate in the study. The study protocol has been approved by the ethics committee of the scientific medical lead (Bernd J. Schmitz-Dräger), that is, the ethics committee of the Bavarian Chamber of

Physicians, Munich, Germany (Committee Number 13108), and subsequently by the ethics committees of all study sites, as noted on the German Clinical Trial website (<https://drks.de/search/en/trial/DRKS00005643>) and in the first full report on efficacy and safety data from the LEAN study [14].

Conflict of Interest Statement

Bernd J. Schmitz-Dräger has acted as a consultant and/or trialist for and has received fees from AstraZeneca, Hexal AG, and Janssen. Ekkehardt Bismarck, Thomas Ebert, and Stephan Mühlich are trialists for Hexal AG. Roland Starlinger and Kerstin Dienes are employees of Sandoz and Hexal AG, respectively. Bertram Ottillinger has acted as a consultant for and has received fees from Hexal AG. Peter J. Goebell has participated in advisory boards for and received honorary fees and/or travel support from Apogepha, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, EUSA, iOMEDICO, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Roche, and Sanofi. Bernd J. Schmitz-Dräger and Oliver W. Hakenberg were members of the journal's Editorial Board at the time of submission. Natalya Benderska-Söder and Jutta Bergler-Klein have no conflicts of interest to declare.

Funding Sources

This study was funded by Sandoz.

Author Contributions

B.J.S.-D. and B.O. were responsible for study conceptualization. B.J.S.-D., E.B., T.E., and S.M. were principal investigators and collected data. B.O. performed the statistics workup. B.J.S.-D., R.S., B.O., and N.B.-S. performed the data analysis and wrote the original manuscript draft. E.B., T.E., K.D., P.J.G., S.M., J.B.-K., and O.W.H. reviewed and edited the manuscript. All authors approved the final version of the manuscript.

Data Availability Statement

All data utilized in this analysis are included in this article and its online supplementary material files. Further inquiries for the LEAN study can be directed to the corresponding author.

References

- Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. *Eur Urol*. 2017;71(4):630–42. <https://doi.org/10.1016/j.eururo.2016.08.002>
- Leitlinienprogramm Onkologie [Internet]. S3-Leitlinie Prostatakarzinom version 6.2. [cited 2024 Mar 19]. Available from: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostatakarzinom_Version_6/LL_Prostatakarzinom_Langversion_6.2.pdf
- Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bittling R, et al. NCCN Guidelines® insights: prostate cancer, version 1.2023. *J Natl Compr Canc Netw*. 2022; 20(12):1288–98. <https://doi.org/10.6004/jnccn.2022.0063>

- 4 European Association of Urology [Internet]. Eau - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. [cited 2024 Mar 19]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-06-13-141145.pdf
- 5 Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. *PLoS One*. 2014;9(9):e107516. <https://doi.org/10.1371/journal.pone.0107516>
- 6 Ng CF, Chiu PKF, Yee CH, Lau BSY, Leung SCH, Teoh JYC. Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study. *Sci Rep*. 2020;10(1):18060. <https://doi.org/10.1038/s41598-020-75139-w>
- 7 US Food and Drug Administration [Internet]. FDA Drug Safety Communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. [cited 2024 Mar 19]. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-update-ongoing-safety-review-gnrh-agonists-and-notification>
- 8 Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. *Circulation*. 2021;144(16):1295–307. <https://doi.org/10.1161/CIRCULATIONAHA.121.056810>
- 9 Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blümle A, Schmucker C, et al. Degarelix for treating advanced hormone-sensitive prostate cancer. *Cochrane Database Syst Rev*. 2021;8(8):CD012548. <https://doi.org/10.1002/14651858.CD012548.pub2>
- 10 Klotz L, Van Komen S, Dragnic S, White WB. Impact of androgen deprivation therapy on cardiovascular outcomes in prostate cancer. *Société Internationale d'Urologie Journal*. 2022;3(4):259–75. <https://doi.org/10.48083/vdnp9678>
- 11 Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. *Cancer*. 2007;110(7):1493–500. <https://doi.org/10.1002/cncr.22933>
- 12 Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. *N Engl J Med*. 2020;382(23):2187–96. <https://doi.org/10.1056/NEJMoa2004325>
- 13 Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*. 2022;43(41):4229–361. <https://doi.org/10.1093/eurheartj/ehac244>
- 14 Schmitz-Dräger BJ, Mühlich S, Lange C, Benderska-Söder N, Bismarck E, Starlinger R, et al. Effectiveness and distribution of testosterone levels within first year of androgen deprivation therapy in a real-world setting: results from the non-interventional German cohort LEAN study. *Urol Int*. 2021;105(5–6):436–45. <https://doi.org/10.1159/000513073>
- 15 US Department of Health and Human Services [Internet]; National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 [cited 2024 Mar 19]. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf
- 16 Okwuosa TM, Morgans A, Rhee JW, Reding KW, Maliski S, Plana JC, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. *Circ Genom Precis Med*. 2021;14(3):e000082. <https://doi.org/10.1161/HCG.0000000000000082>
- 17 Powell K, Burns MC, Prasad V. Relugolix: five reasons why the US Food and Drug Administration should have exercised restraint. *Eur Urol*. 2023;83(2):101–2. <https://doi.org/10.1016/j.eururo.2022.08.029>
- 18 Merola D, Schneeweiss S, Sreedhara SK, Zabolka LE, Quinto K, Concato J, et al. Real-world evidence prediction of a phase IV oncology trial: comparative degarelix vs leuprolide safety. *JNCI Cancer Spectr*. 2022;6(4):pkac049. <https://doi.org/10.1093/jncics/pkac049>
- 19 Crawford ED, Hafron JM, Debruyne F, Wallis C, Chang S, Garnick MB. Cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a gonadotropin-releasing hormone antagonist. *J Urol*. 2024;211(1):63–70. <https://doi.org/10.1097/JU.0000000000003721>
- 20 Cicione A, Nacchia A, Guercio A, Gravina C, Franco A, Grimaldi MC, et al. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. *Prostate Cancer Prostatic Dis*. 2023;26(4):765–71. <https://doi.org/10.1038/s41391-022-00640-4>
- 21 Chan JSK, Lee YHA, Hui JMH, Liu K, Dee EC, Ng K, et al. Long-term cardiovascular risks of gonadotropin-releasing hormone agonists and antagonists: a population-based cohort study. *Clin Oncol (R Coll Radiol)*. 2023;35(6):e376–83. <https://doi.org/10.1016/j.clon.2023.03.014>
- 22 Nelson AJ, Lopes RD, Hong H, Hua K, Slovin S, Tan S, et al. Cardiovascular effects of GnRH antagonists compared with agonists in prostate cancer: a systematic review. *JACC CardioOncol*. 2023;5(5):613–24. <https://doi.org/10.1016/j.jaccao.2023.05.011>
- 23 Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, et al. Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. *Urol Oncol*. 2021;39(1):52–62. <https://doi.org/10.1016/j.urolonc.2020.08.003>